Tfpi - tissue factor pathway inhibitor Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 29436

Summary

Predicted to enable serine-type endopeptidase inhibitor activity. Involved in cellular response to interleukin-1; cellular response to lipopolysaccharide; and response to estradiol. Located in extracellular space. Biomarker of atrial fibrillation; disseminated intravascular coagulation; myocardial infarction; and osteonecrosis. Human ortholog(s) of this gene implicated in several diseases, including Factor VIII deficiency; osteonecrosis; thrombophilia (multiple); toxic shock syndrome; and transient cerebral ischemia. Orthologous to human TFPI (tissue factor pathway inhibitor). [provided by Alliance of Genome Resources, Apr 2022]

Tfpi Products (2)

mRNA Protein Name
NM_001177321.1 NP_001170792.1 tissue factor pathway inhibitor isoform 2 precursor
NM_017200.1 NP_058896.1 tissue factor pathway inhibitor isoform 1 precursor

Gene Ontology

  • Biological Process
  • Cellular Component
Biological Process GO Annotation Evidence References Source
involved in cellular response to interleukin-1 IEP
IEP: Inferred from expression pattern
11816723 RGD
involved in cellular response to lipopolysaccharide IEP
IEP: Inferred from expression pattern
11816723 RGD
involved in response to estradiol IEP
IEP: Inferred from expression pattern
15857755 RGD
involved in response to lipopolysaccharide IEP
IEP: Inferred from expression pattern
9426395 RGD
Cellular Component GO Annotation Evidence References Source
located in extracellular space IDA
IDA: Inferred from direct assay
12083485 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

tissue factor pathway inhibitor

  • EPI

  • LACI

  • extrinsic pathway inhibitor

  • lipoprotein-associated coagulation inhibitor

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P99283 Concizumab 98.12% Unkown

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-153480A ARC19499 sodium Inhibitor 99.40% Phase 1
Inhibitory Antibodies (2)
Cat. No. Product Name Effect
Purity Phase
HY-P99725 Marstacimab 96.27% Phase 3
HY-P99465 Befovacimab Inhibitor 97.31% Phase 2

Pre-clinical Phase

Bioactive Molecules (7)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-153480 ARC19499 Inhibitor 93.65% Unkown
HY-RS14427 TFPI Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS14428 TFPI2 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS17298 Tfpi Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS18411 Tfpi2 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23753 Tfpi Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS24892 Tfpi2 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (1)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P991379 MG1113A Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Tfpi NCBI NCBI:7035